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MonoubiquitylatedSubstrate ubiquitylation is a reversible process critical to cellular homeostasis that is often dysregulated in
many human pathologies including cancer and neurodegeneration. Elucidating the mechanistic details of
this pathway could unlock a large store of information useful to the design of diagnostic and therapeutic in-
terventions. Proteomic approaches to the questions at hand have generally utilized mass spectrometry (MS),
which has been successful in identifying both ubiquitylation substrates and proﬁling pan-cellular chain link-
ages, but is generally unable to connect the two. Interacting partners of the deubiquitylating enzymes (DUBs)
have also been reported by MS, although substrates of catalytically competent DUBs generally cannot be.
Where they have been used towards the study of ubiquitylation, protein microarrays have usually functioned
as platforms for the identiﬁcation of substrates for speciﬁc E3 ubiquitin ligases. Here, we report on the ﬁrst
use of protein microarrays to identify substrates of DUBs, and in so doing demonstrate the ﬁrst example of
microarray proteomics involving multiple (i.e., distinct, sequential and opposing) enzymatic activities. This
technique demonstrates the selectivity of DUBs for both substrate and type (mono- versus poly-) of
ubiquitylation. This work shows that the vast majority of DUBs are monoubiquitylated in vitro, and are inca-
pable of removing this modiﬁcation from themselves. This work also underscores the critical role of utilizing
both ubiquitin chains and substrates when attempting to characterize DUBs. This article is part of a Special
Issue entitled: Ubiquitin Drug Discovery and Diagnostics.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Ubiquitin ligases (E3s) represent the largest family of proteins in
humans (~620) [1], and largely determine the substrate speciﬁcity
of ubiquitin transfer to target proteins. De-ubiquitylase enzymes
(DUBs), in contrast, remove ubiquitin from proteins to recycle
ubiquitin and facilitate proteasomal degradation of substrates, to
modify the nature of the linkage (editing), to terminate the signal,
and/or to attenuate proteasomal degradation [2]. Ubiquitin itself is
found singly on proteins as well as in chains of various linkages, a ref-
erence to which of seven lysines of ubiquitin are used to join adjacent
moieties within a chain. Much remains to be elucidated concerning
the biological meaning of the various linkages, but the current para-
digm holds that chains linked through lysine-48 of ubiquitin (K48ctrometry; PTM, post-transla-
the forty-eighth amino acid of
quitin, a lysine; TUBEs, tandem
2c is the catalytic core domain
crylamide gel electrophoresis
biquitin Drug Discovery and
ay, Malvern, PA 19355, USA.
rights reserved.chains) signal proteasomal degradation and K63-linked chains are
signaling events that modify protein location, interaction, and/or
function [3].
Of the two activities regulating substrate ubiquitylation, the E3s
have garnered the majority of research interest to date. Despite this
fact, it is the DUBs that have attracted the most attention for diagnos-
tic and therapeutic targeting. Reasons for this preference include the
simplicity of ubiquitin removal relative to conjugation, a process re-
quiring orchestrated action of three enzymes; the lack of functional
redundancy among DUBs relative to the E3s (there are only ~90
DUBs [4,5]); and the success of VelcadeTM (Millennium Pharmaceuti-
cals), a proteasome inhibitor that functionally resembles pan-DUB in-
hibition. Selective DUB inhibition therefore provides an opportunity
for therapeutic efﬁcacy, with decreased likelihood of side effects rela-
tive to approaches targeting the whole proteasome.
It is well established that E3s are capable of autoubiquitylation
[6–9] and that many DUBs interact directly with E3s [5]. These DUBs
antagonize E3 autoubiquitylation and/or substrate ubiquitylation [10]
but little attention has been paid to conversation in the opposite direc-
tion, E3 activity towards the DUB. A brief survey of proteomic literature
revealed that many DUBs have themselves been putatively identiﬁed
as being ubiquitylated [11,12] in addition to a handful that have been
deﬁnitively demonstrated as such [13–19]. We therefore took advan-
tage of a DUB protein microarray to investigate the extent of DUB
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proteins can be ubiquitylated in vitro. Furthermore, through the
use of DUB-speciﬁc antibodies and polyubiquitin speciﬁc tandem
ubiquitin binding entities (TUBEs; [20]), we demonstrate that mon-
oubiquitylation is the predominant form of modiﬁcation even in
vitro among these enzymes. Finally, given the ability of E3s to
ubiquitylate themselves, we investigated whether or not the DUBs
could remove or prevent their own modiﬁcation, and found that
most could not. Indeed, most were found incapable of completely
deubiquitylating other DUBs as well. Interestingly, several different
activity proﬁles were discovered from among the DUBs examined;
proﬁles revealed by the use of actual substrates with isopeptide-
linked ubiquitin chains. Particularly in high throughput, this sub-
strate/chain proﬁling is impossible via MS or alternative biochemical
means (e.g., ubiquitin rhodamine or free chains). To our knowledge,
this is the ﬁrst demonstration of microarray proteomics towards the
investigation of substrates for enzymes that remove post transla-
tional modiﬁcations (PTMs); we believe the technique will also
prove informative to the study of other reversible PTMs (phosphor-
ylation for example).
2. Materials and methods
2.1. Protein production
Protein production as previously described [21].
2.2. Array production
Array production by GenTel Biosciences, Inc (Madison, WI) as pre-
viously described [21].
2.3. Array ubiquitylation
Arrays, stored at −80 °C were equilibrated to room temperature
for 1 h prior to opening package seals to prevent condensation from
forming on the array. Arrays were then placed into GenTels SIMplex
16‐Multi Array system (catalog #4-1001). Microarrayed proteins
were ubiquitylated by adding 100 μl per subarray of 5 nM E1 (Ube1;
LifeSensors #UB101), 100 nM E2 (UBE2D3; LifeSensors #UB201),
20 nM each E3 (as indicated in text; LifeSensors), 0.02 mg/ml
ubiquitin (LifeSensors #SI201), and 200 μM ATP (Sigma Aldrich) in
array ubiquitylation buffer (50 mM Tris pH 8, 50 mM NaCl, 50 mM
MgSO4, 0.1% Tween-20, 1 mM dithiothreitol, 1% bovine serum albu-
min); reactions were incubated at room temperature for 1 h. Each
subarray was washed once with 200 μl phosphate buffered saline
with 0.05% Tween-20 (PBST), then three times with phosphate buff-
ered saline (PBS). Arrays were then deubiquitylated or directly visu-
alized, but always kept wet. Lysate-driven ubiquitylation was done
by diluting lysate (made as described below) into lysis buffer to the
indicated concentrations, and applying directly to arrays for 1 h at
room temperature. Arrays were then washed free of lysate (as
above) and visualized (Section 2.5).
2.4. Deubiquitylation of pre-ubiquitylated arrays
After washing, arrays were incubated for 1 h with 100 nM of the
indicated DUB (LifeSensors, Inc.) in deubiquitylase buffer (20 mM
Tris pH 7.5, 150 mM NaCl, 10 mM dithiothreitol, 0.05% CHAPS). Ar-
rays were then washed as described in Section 2.3.
2.5. Array-signal detection
Array-signal detection using TUBEs was as previously described
[22]; FK2 (Millipore) detection was with primary antibody diluted1:1000 in PBST, and ﬂuorescein-conjugated anti-mouse (Rockland
210–1201) 1:50 in PBST.2.6. Lysate preparation
HEK293T cells were grown in 10 cm dishes to 80–90% conﬂuency.
When stated, cells were treated with 50 μM pan-DUB inhibitor PR-
619 (LifeSensors, Inc.) for 1–2 h. Cells were harvested by scraping in
ice cold PBS and collected by centrifugation (3000 rpm). Cell pellets
were subjected to one freeze–thaw cycle (−80 °C) and resuspended
in cold cell lysis buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1%
NP-40, 1% sodium deoxycholate, 10% glycerol, 1 mM PMSF, protease
inhibitor cocktail and 20 μg/ml aprotinin) and vortexed several
times. Lysates were centrifuged at 13,000 rpm for 20 min at 4 °C
and supernatants collected.2.7. SDS PAGE gel electrophoresis, protein transfer to nitrocellulose
membrane and Western blots
SDS PAGE gel electrophoresis, protein transfer to nitrocellulose
membrane and Western blots were all done under standard condi-
tions and procedures except for the following: blots with LifeSensors'
biotin-conjugated TUBEs required blocking in 3% bovine serum albu-
min; blots with LifeSensors' VU-1 anti-ubiquitin were incubated after
transfer with 0.5% gluteraldehyde/0.1 M potassium phosphate buffer
pH 7.0 for 20 min, and primary incubation was done overnight at
4 °C. All reagents were diluted according to manufacturer's instruc-
tions; secondary reagents used were goat anti-rabbit-HRP (Rockland
#211-1302), peroxidase conjugated avidin (Rockland #A003-03),
and goat anti-mouse HRP (Sigma #A4416). Chicken IgY antibodies
to UCHL5 and JOSD1 (LifeSensors, Inc.) were used at 1:1000 dilution
in PBST and visualized with horseradish peroxidase-conjugated rab-
bit anti-chicken IgY (Rockland #803-4302) diluted 1:2000 in PBST.2.8. DUB activity
DUB activity was assayed using CHOP reporter assay as previously
described [22], or by using di-ubiquitin IQF substrates (LifeSensors,
Inc.) according to manufacturer's instructions.2.9. E3 ligase activity
E3 ligase activity was measured using the E3Lite Assay as previ-
ously described [23]. Also in modiﬁed form using a mixture of E3s
(where stated) consisting of Praja1, Murf1, and Carp2; and further
modiﬁed (where stated) by the addition of DUBs (as listed) to the
assay wells for 1 hour incubation at room temperature following the
initial ubiquitylation reaction.2.10. In vitro ubiquitylation/deubiquitylation reactions
Soluble proteins were ubiquitylated by adding 5 nM E1 (Ube1;
LifeSensors #UB101), 100 nM E2 (UBE2D3; LifeSensors #UB201),
20 nM each E3 (as indicated in text; LifeSensors), 0.02 mg/ml
ubiquitin (LifeSensors #SI201), and 200 μM ATP (Sigma Aldrich)
into reactions containing 200 ng substrates (as indicated), all in
ubiquitylation buffer (50 mM Tris8, 5 mM MgCl2, 0.1% Tween-20,
1 mM 2-mercaptoethanol). Reactions were incubated at room tem-
perature for 1 h. Where indicated, a second DUB was added to the re-
action (concentrations listed in ﬁgure), which was allowed to
proceed for an additional hour. At the end of reactions, 6× SDS sam-
ple buffer was added, and reactions loaded into PAGE, or stored at
−20 °C until later PAGE analysis.
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3.1. DUBs are ubiquitylated by various E3s
We tested various E3s for the ability to ubiquitylate a microarray of
immobilized DUBs previously developed and described (DUB Chip)
[21,24]. This protein microarray consisted of approximately 40 DUB
and ubiquitin-like isopeptidases and enabled us to investigate various
conditions under which some of themmight be ubiquitylated. Multiple
identical arrays were incubated with solution containing E1, E2,
ubiquitin, and ATP. Ubiquitylation reactions were initiated by the addi-
tion of various E3s into duplicate arrays, individually or in combinationFig. 1. Ubiquitylation of DUB Chip. A. Individual, identical protein microarrays were ubiquit
(Praja1, Carp2, and Murf1), or using reaction mixture lacking an E3 (“No E3”). All substrate
arrays. One of the two was visualized using antibody capable of seeing monoubiquitylation e
(right column of arrays labeled “TUBEs”). B. E3Lite assay (LifeSensors, Inc.) data (signal ve
(either free or E3-conjugated). C. Data from ubiquitylation reactions (A) visually organize
array ubiquitylated with E3 mix and visualized with TUBEs; all other columns represent
USP20, 2. USP51c, 3. USP5, 4. Ataxin3, 5. USP7c, 6. AMSH, 7. Otubain1, 8. JOSD1, 9. UCHL3,
like, 17. USP33c, 18. USP15, 19. USP28, 20. sseL, 21. USP18, 22. DEN1, 23. PLPro, 24. SENP
JOSD2, 33. YOD1, 34. UCHL1, 35. USP21c, 36. Ubiquitin, 37. Ulp1c, 38. PLP2, 39. USP4.(rows as listed in Fig. 1A). All arrayswere then thoroughlywashed to re-
move soluble reaction components. Finally, within each experimental
condition tested, one of the two identically ubiquitylated arrays was vi-
sualized using either an antibody towards ubiquitin (FK2) as the prima-
ry detection reagent, or biotinylated tandem ubiquitin binding entities
(TUBEs). While the antibody recognizes ubiquitin conjugated to sub-
strate individually (monoubiquitylation) as well as in chains (poly-
ubiquitylation), TUBEs are speciﬁc to detection of polyubiquitylation
events [20] without preference to speciﬁc chain linkage [25]. The ab-
sence of signal from reactions lacking E3 demonstrated that observed
signals were ubiquitylation dependent (bottom row, Fig. 1A). Each of
the E3s shown in Fig. 1A was capable of ubiquitylating a distinct butylated with ﬁve different E3s (individually as listed), a mixture of three labeled “mix”
s were printed in triplicate, and all conditions were tested on two separate (identical)
vents (left column of arrays labeled “Ab”); the other using polyubiquitin-speciﬁc TUBEs
rsus time) showing all E3s used in (A) were capable of forming polyubiquitin chains
d by E3 (columns) and substrate (rows). The column labeled “TUBEs” represents the
data from arrays visualized with antibody. The identities of substrates by row are: 1.
10. USP8c, 11. UCHL5, 12. SENP6c, 13. SENP1c, 14. USP21, 15. Otubain2, 16. Ataxin3-
2, 25. USP34c, 26. USP14, 27. USP8, 28. hSTAM1, 29. USP2c, 30. USP7, 31. BAP1, 32.
Fig. 2. Deubiquitylation of DUB Chip. A. Sixteen identical protein microarrays were all ubiquitylated with E3 mix (Praja1, Carp2, and Murf1). After washing away soluble
ubiquitylation machinery, individual DUBs (as listed, including mock-treated arrays labeled “No DUB”) were applied to separate arrays, which were then visualized by antibody
capable of seeing monoubiquitylation events. Loss of signal indicates putative substrates of the DUB tested. B. Array data from (A) visually organized by DUB tested (columns)
and ubiquitylated substrates (rows). The identities of substrates by row are: 1. USP20, 2. USP51c, 3. USP5, 4. Ataxin3, 5. USP7c, 6. AMSH, 7. Otubain1, 8. JOSD1, 9. UCHL3, 10.
USP8c, 11. UCHL5, 12. USP21, 13. Otubain2, 14. Ataxin3-like, 15. USP33c, 16. USP15, 17. USP28, 18. sseL, 19. DEN1, 20. PLPro, 21. USP14, 22. USP8, 23. hSTAM1, 24. USP2c, 25.
USP7, 26. BAP1, 27. YOD1, 28. UCHL1, 29. USP21c, 30. Ubiquitin, 31. Ulp1c, 32. PLP2, 33. USP4. C. Experiment identical to that described in (A), except that the array was visualized
using polyubiquitin-speciﬁc TUBEs. D. Array data from (C) visually organized by DUB tested (columns) and ubiquitylated substrates (rows, as above).
2072 C.M. Loch, J.E. Strickler / Biochimica et Biophysica Acta 1823 (2012) 2069–2078
2073C.M. Loch, J.E. Strickler / Biochimica et Biophysica Acta 1823 (2012) 2069–2078overlapping subset of immobilized DUBs (rows 1–5 left column) and
appeared to work additively when co-incubated (row 6); interestingly,
Praja1 was the only E3 tested that exhibited an ability to poly-
ubiquitylate these substrates (rows 1–5, compare left and right col-
umns). On the other hand, all of these E3s were capable of forming
polyubiquitin chains in concert with UBE2D3 in the E3Lite
autoubiquitylation assay (Fig. 1B). A summary of all recombinant E3/
immobilized substrate ubiquitylation events is shown in Fig. 1C. Togeth-
er, these results show that 1) the vast majority of DUBs were
ubiquitylated in vitro, 2) most E3s tested were capable of effecting
this modiﬁcation, 3) the events appeared to be predominantly mono-
ubiquitylation, and 4) the substrates themselves inﬂuenced the extent
of ubiquitylation (i.e. mono- versus poly-) in an E3 dependent manner.
3.2. Proﬁling DUBs against multiplexed ubiquitylated substrates
Based on the observation that these E3s together ubiquitylated the
vast majority of proteins immobilized on the array, we speculated
that this ubiquitylated array might provide a powerful tool toFig. 3. DUBs examined for behavior against ubiquitylated substrates were active enzymes. A
by CHOP reporter assay (LifeSensors, Inc.), except AMSH. B. AMSH was examined for activity
an internally quenched ﬂuorophore pair. As expected, activity was speciﬁc to K63-linkage
ubiquitylated with E3 mix (Praja1, Carp2, Murf1) and then mock treated with DUB (“No D
with DUB (“Not UB'd”); or ubiquitylated with E3 mix and then treated with DUB enzyme (examine the behavior of certain deubiquitylase enzymes against mul-
tiple ubiquitylated substrates in parallel. To maximize ubiquitylation
events on the array, we utilized a cocktail of E3s (Murf1, Carp2,
Praja1). After 1 h, soluble ubiquitylation reaction components were
removed from the arrays which were then thoroughly washed before
soluble DUBs were applied to the ubiquitylated array (as listed
Figs. 2A,C) and incubated for another hour. Washed and dried arrays
were then visualized for total ubiquitylation (mono- and poly-;
Fig. 2A) or polyubiquitylation events (Fig. 2C), as above. Loss of signal
between an array incubated with DUB compared to one mock treated
would indicate putative substrates of that DUB. Complete array data
for every combination of immobilized substrate and soluble enzyme
is presented as Figs. 2B,D. Results indicated that the vast majority of
these DUBs were unable to cleave ubiquitin from the immobilized
substrates. To verify that the enzymes were enzymatically competent,
they were assayed using the CHOP reporter system (LifeSensors, Inc.,
Fig. 3A). All enzymes tested displayed activity by this assay, save
AMSH. Since this DUB is known to prefer K63 linked chains, we incu-
bated it with a K63 linked internally quenched ﬂuorescence based di-. The fourteen DUBs examined in Fig. 2 all showed activity (signal versus time over 1 h)
(versus time over 1 h) against different substrates, di-ubiquitin substrates labeled with
of the diubiquitin. C. E3Lite assay data (endpoint RFU signal) for triplicate wells either
UB”); mock ubiquitylated using reaction mixture lacking an E3 and then mock treated
as listed).
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zyme displayed robust activity against this substrate, demonstrating
that deﬁning activity varies by assay. With this point in mind, we
also tested each of the DUBs for their ability to reverse poly-
ubiquitylation signals in the E3Lite assay, which captures and reports
autoubiquitylated E3s. As seen in Fig. 3C, utilizing the E3 mix resulted
in signal 40-fold higher than the reaction mix lacking an E3. With the
possible exceptions of JOSD1, JOSD2, and K63 speciﬁc AMSH [26,27],
all DUBs tested demonstrated activity for shortening or removing
E3-linked polyubiquitin chains by appreciably reversing the assay sig-
nal, including even K48 speciﬁc UCHL5 [26]. Importantly, many DUBs
were capable of complete signal reversal (USP2c, USP7, USP8c, USP15,
USP21c, USP28, PLP2; and 87% reversal for PLPro).
Like the ubiquitylated protein microarray, the modiﬁed E3Lite
assay described above (Fig. 3C) results in immobilization of
ubiquitylated proteins (the E3s) presented as potential substrates toFig. 4. Proﬁling DUB activity requires both chains and substrates. Data from Fig. 2B and
D has been arranged to better illustrate activity differences among the DUBs proﬁled.
Five DUB proﬁles are shown (vertical labels left of the ﬁgure). The activity of each of
these DUBs is shown against ﬁve rows of ubiquitylated substrates (labeled right of
the ﬁgure for the ﬁrst proﬁle only). The ﬁrst four rows of substrates are invariant
among all proﬁles. The variable rows (labeled *) for each of the ﬁrst three proﬁled
DUBs are intended to show the extent of self-cleavage for these proﬁled enzymes,
and thus are immobilized USP21c, USP28, and USP15, respectively. Within the last
two DUB proﬁles (PLP2 and PLPro) the variable rows are intended to show putative
substrates (UCHL1 and USP4, respectively). The boxed column (of triplicate features)
shows the effect of treatment of ubiquitylated substrates with each of the DUBs pro-
ﬁled, and is shown in between the maximum possible signal to the left (No DUB)
and minimum possible signal to the right (USP8c, a non-speciﬁc and highly active
DUB). Data is shown from arrays reporting polyubiquitin only (TUBEs detection) and
from arrays showing mono- and poly‐ubiquitylation events (Antibody). Complete pro-
ﬁles, arranged identically, are shown in Supplementary Figs. 1–5.DUBs in solution phase. The eight DUBs capable of nearly complete
E3Lite signal reversal (listed above) thus demonstrated an ability to
function under these parameters, and enabled a more careful look
at their behavior towards different substrates, ubiquitylated DUBs.
As shown in Fig. 2A the catalytic domains of USP2 and USP8 were
each capable of completely deubiquitylating the microarray. The cat-
alytic domain of USP21, on the other hand, appeared more selective
in its substrate preference (Figs. 4, and S1). Although the absence of
non-catalytic regulatory regions tempers the ability to draw conclu-
sions, it was nonetheless interesting that USP21c appeared to cut
“all or nothing”. That is, wherever USP21c shortened chains it also
removed the ﬁnal monoubiquitin. USP28 displayed little selectivity
towards shortening substrate-bound chains (aside from its inability
to act on Ataxin3-like), but was incapable of complete substrate
deubiquitylation for any of the substrates examined (Figs. 4, S2). A
fourth pattern emerged from analysis of USP15 data (Figs. 4, S3);
which appeared incapable of completely deubiquitylating any of the
substrates examined, yet displayed substrate selectivity for chain
shortening. PLP2 (NL63 Coronavirus) identiﬁed JOSD1 and UCHL1 as
putative substrates (Figs. 4, S4); PLPro (SARS Coronavirus) identiﬁed
USP4 as a putative substrate and was the only DUB examined that
displayed an ability to shorten chains bound to Ataxin3-like (Figs. 4,
S5). Notably, there were no DUBs (save catalytic domains) capable
of de(mono)ubiquitylating themselves; all DUBs examined were ca-
pable of cleaving free chains (Fig. 2D row 30).3.3. Veriﬁcation of array-based observations
Because ubiquitylation of array-immobilized DUBs could in theory
be a technical artifact of their immobilization (e.g., surface-driven
conformational change that exposes an otherwise inaccessible ly-
sine), various DUBs were selected for in vitro ubiquitylation reactions
in solution phase with Murf1 as the E3. We used polyubiquitin-
speciﬁc TUBEs (Fig. 5A) and observed enhanced high molecular
weight smearing (characteristic of polyubiquitylation) in reactions
containing most DUBs as compared with the no DUB control. The re-
actions containing USP2c and USP8c were exceptions inasmuch as
there was no discernible ubiquitylation in either, likely reﬂecting
the high and indiscriminate deubiquitylase activity of both of these
catalytic domains (see Figs. 2A and 3).
Although conﬁrmatory of DUBs being ubiquitylated per se, poly-
ubiquitylation observed in solution versus monoubiquitylation on
the array suggested that chain formation might have been antago-
nized on the array by substrate immobilization. Alternatively, the
observed polyubiquitylation seen in solution might represent en-
hanced E3 autoubiquitylation activity. To differentiate E3 and DUB
ubiquitylation, we used antibodies against UCHL5 and JOSD1 to visu-
alize solution-based in vitro ubiquitylation reactions. UCHL5 has been
implicated by MS-based proteomics as being ubiquitylated, but this
has not been independently validated [11]. JOSD1 has never been
reported to be ubiquitylated. As shown in Fig. 5 both UCHL5
(Fig. 5B) and JOSD1 (Fig. 5C) were exclusively mono-ubiquitylated
in vitro. To further distinguish these possibilities (i.e., E3 auto-
ubiquitylation and DUB ubiquitylation), Murf2 (shown by array to
monoubiquitylate DUBs) was included in ubiquitylation reactions
with UCHL5 (shown by array to be ubiquitylated by Murf2). As seen
in Fig. 5D (lane 2), and in agreement with Fig. 5A, a high molecular
weight smear was observed when all reaction components were sol-
uble. However, prior immobilization of the E3 to the wells of the plate
abrogated the appearance of these high molecular weight proteins
from the remaining solution-based components and resulted in a sin-
gle distinct band consistent in size with monoubiquitylated UCHL5
(Fig. 5D lane 3).
As another test of DUB ubiquitylation (and the extent thereof), we
made lysate of HEK293T cells and applied it to DUB Chip in various
Fig. 5. E3 auto(poly)ubiquitylation and DUB monoubiquitylation in gel. A. Ubiquitylation
reactions with Murf1 (shown by array to monoubiquitylate DUB substrates) as the E3
were run in the presence of variousDUBs. Reactionswere SDS PAGE separated, transferred
to nitrocellulose, and probed with TUBEs to observe any high molecular weight poly-
ubiquitylation. Most reactions with DUBs displayed enhanced smearing characteristic of
polyubiquitylation, compared to the reaction containing no DUB (ﬁrst lane). B. Antibody
to UCHL5was used to probe separated reaction components from complete ubiquitylation
reactions including Praja1 as the E3 (shown by array to be capable of DUB poly-
ubiquitylation) andUCHL5 as substrate (column labeled (+)). Inclusion of all components
except Praja1 (column labeled “-E3”) showed that the observed 8 kD shift (indicated by
arrow) above the predominant form of the substrate was ubiquitylation dependent.
Similarity of this lane to one containing only UCHL5 protein substrate (column labeled
“Pr”) conﬁrms that the antibody was not cross reacting to any ubiquitylation machinery
(e.g., ubiquitin or charged E2). C. Identical to Fig. 5B except that blot was visualized with
anti-JOSD1 antibody, and JOSD1 was the substrate included in the reactions (or protein
alone lane). D. Ubiquitin antibody (VU1) was used to visualize (via immunoblot) soluble
components of in vitro ubiquitylation reactions in which E3 was pre-immobilized to the
surface of the well (and therefore not present in the gel/blot) and DUB omitted (negative
control, lane 1); where all components were soluble including UCHL5 as substrate
(positive control, lane 2); and where UCHL5 was included but the E3 (Murf2) was again
pre-immobilized to the well surface (lane 3). Arrow indicates expected size of
monoubiquitylated UCHL5.
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oughly washed, then probed for ubiquitin (either FK2 or TUBEs for
observing mono- and poly‐events, respectively). As shown in
Fig. 6A, the lysate was capable of ubiquitylating immobilized DUBs
in a manner consistent with monoubiquitylation. Because the lysate
presumably contained various E3s and DUBs, the observed mono-
ubiquitylation might have reﬂected either deposition of a single
ubiquitin or the net effect of DUBs attenuating initially assembledchains. New arrays were therefore treated with HEK293T lysate that
had been made in the presence of the pan-DUB inhibitor PR619
(LifeSensors, Inc.) to antagonize DUB activity (e.g., chain shortening).
Results were indistinguishable from the untreated lysate (data not
shown). This suggested that, consistent with our earlier data
(Fig. 1A), DUB monoubiquitylation is a product of single-moiety de-
position as opposed to chain shortening. A summary of lysate driven
ubiquitylation for each of the proteins on the array is shown as
Fig. 6B.
For the purposes of verifying array-based deubiquitylation, select-
ed DUBs (the ‘substrates’) were included in complete ubiquitylation
reactions for 30 min, at which point a second DUB was added and
the reactions were allowed to proceed for an additional hour. Reac-
tion components were then separated by SDS PAGE, transferred to
membrane, and probed with antibodies to the DUB ‘substrates’ ini-
tially present (JOSD1 and UCHL5) to observe their ubiquitylation sta-
tus. In agreement with array data, USP2c and USP21c removed
ubiquitin from both substrates; PLP2 from only one (ubiquitylated
JOSD1); and Ataxin3 showed no activity towards either (Fig. 7).
4. Discussion
Of the eighteen DUBs reported to be ubiquitylated in vivo, our
array contained twelve: AMSH [13], USP4 [14], USP7 [15,16], USP15
[17], USP20 [18], Ataxin 3 [11,12,19], Bap1 [11], Otub1 [11], UCHL3
[11], UCHL5 [11], USP14 [11], and USP5 [12], all of which were here
conﬁrmed as targets of in vitro ubiquitylation. Five of these twelve
(Bap1, Otub1, UCHL3, UCHL5, USP14) were initially identiﬁed as
ubiquitylated in HeLa cells via MS proteomics [11] but never indepen-
dently conﬁrmed. This study, therefore, represents their ﬁrst in vitro
conﬁrmation as targets of ubiquitylation and suggests putative E3s.
Of the 39 substrates examined on the array, the only ubiquitin and
ubiquitin-like proteases not ubiquitylated by recombinant E3 mix
were SENP1c, SENP6c, and JOSD2. One of these, SENP6c, was
ubiquitylated by the lysate, suggesting that our mix lacked an appro-
priate E3 for this target. UCHL1 was not ubiquitylated by the lysate,
despite having been when recombinant E3s were used. This suggests
that either the observed in vitro ubiquitylation was artifactual, the ly-
sate used did not contain an appropriate ligase for this substrate, or
the lysate contained an UCHL1-speciﬁc DUB. Otherwise, the recombi-
nant mix of E3s and the lysate were surprisingly consistent in terms
of which substrates were ubiquitylated.
The inability to represent all possible E3/substrate pairings is one
explanation for the false negatives that unavoidably accompany any
proteomic experiment (MS or array-based). False positives are also
inherent to proteomic investigation. In the case of MS-based studies,
false positives usually represent indirect effects (for example, pro-
teins identiﬁed as hyper-ubiquitylated following DUB mutation/dele-
tion might be substrates for an E3, the inhibitor of which was
increasingly degraded by the loss of DUB activity). Array-based prote-
omics deﬁnitively demonstrate direct-effects, but cannot inform as to
biological relevance; false positives in this setting generally reﬂect
two proteins capable of interaction that otherwise never do so in
cells. However conﬁgured, proteomics provides the leads but veriﬁca-
tion is always required to sort the wheat from the chaff. Cross-
complementary strengths and weaknesses make MS and array-
based proteomics reciprocal, and suggest a rapid and high-
throughput workﬂow. Namely, performing both types of experiments
for the same protein(s) of interest and cross referencing resultant
data sets for common hits would identify directly interacting proteins
whose interaction occurs in vivo. A slightly modiﬁed example of such
an approach is the current in vitro veriﬁcation of in vivo results for
Bap1, Otub1, UCHL3, UCHL5, and USP14, previously suggested by
MS to be ubiquitylated.
The proteomic alternative to DUB substrate identiﬁcation (i.e., MS)
relies upon a residual di-glycine signature of tryptic ubiquitylated
Fig. 6. HEK293T lysate-driven ubiquitylation of DUB Chip. A. Duplicate protein microarrays were incubated with straight cell lysate (i.e., no inhibitors) at various dilutions, washed,
then probed with either antibody (FK2, Millipore; left column) to visualize monoubiquitylation events, or TUBEs (LifeSensors, Inc.) to visualize polyubiquitylation (right column). B.
Antibody-visualized data from the above experiment, organized by concentration of lysate (columns) versus substrate (rows, organized and labeled identically to those in Fig. 1C).
Note that while most substrates showed dose-dependent ubiquitylation, some were eliminated from analysis by high FK2 background even in the absence of cell lysate (e.g., col-
umn 1, rows 10, 29, 35, 36).
Fig. 7. Deubiquitylation of soluble ubiquitylated substrates. In vitro ubiquitylation reactions with Praja1 as the E3 were performed in the presence of either JOSD1 or UCHL5 as the
intended substrate. After 30 min, a second deubiquitylase enzyme (either USP2c, USP21c, PLP2, or Ataxin3, as indicated) was added to the reactions which were then incubated for
another hour. Shown are immunoblots of the separated reaction components probed with primary antibody against the corresponding intended substrate (JOSD1 or UCHL5).
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extent of initial ubiquitylation (chain versus mono), or linkage speciﬁc
activity. Alternative in vitro techniques have proﬁled the activity of
DUBs towards artiﬁcial non-isopeptide linked substrates (e.g., UB-
Rhodamine) or free chains completely devoid of substrate [27,28].
Such experiments do not well reﬂect DUB physiology, since most
DUBs do not exist in cells to recognize and cleave free chains (IsoT
excepted [29]). The importance of looking at actual substrates with
isopeptide-linked chains demonstrated here (Figs. 5, and S1–S5) is
intuitively underscored by noting the presence in human (and most
eukaryotes) of more DUBs (~ninety) than unique chain topologies
(eight). To our knowledge, this is the ﬁrst proteomic study of
deubiquitylase activity involving true protein substrates that also dis-
criminates between ubiquitin chain shortening versus complete
deubiquitylation.
The techniques described here should prove widely informative
when applied on a wider proteomic scale (e.g., utilizing a larger,
more representative microarray like ProtoArray from Invitrogen, an
array containing over 9000 human proteins) and should facilitate in-
vestigation into reversal of other PTMs as well (proﬁling phospha-
tases, for example). Simple procedural modiﬁcations, like utilizing
different E2/E3 combinations, or using single-lysine ubiquitin mu-
tants to drive homogeneous chain formation further expand the in-
formation potential. Even the current study, which utilized a small
array of a single family of enzymes, a single E2 (UBE2D3) reported
to form both K11 and K48 linked chains [30], and wild-type ubiquitin,
revealed an unexpectedly large breadth of insight into biology of the
pathway represented.
The present study demonstrated, most obviously, that the majori-
ty of DUBs can be ubiquitylated, and that the predominant form of
this modiﬁcation is monoubiquitin. We showed that most E3s tested
are capable of effecting this modiﬁcation for a distinct but over-
lapping set of substrates. Because most E3s transferred only a single
ubiquitin (Figs. 1A, 5B–D, 6A, and 7) despite being shown capable of
auto-polyubiquitylation, we know that there was only one acceptor
lysine per DUB; this highlights the degree of speciﬁcity maintained
in vitro considering that, for example, JOSD1 has 15 lysines and
UCHL5 has 25. Because we identiﬁed an E3 capable of DUB poly-
ubiquitylation (Praja 1, Fig. 1A), we know that even in vitro, the sub-
strate is capable of inﬂuencing the extent to which the modiﬁcation
occurs in an E3-dependent manner. The fact that cell lysates also
monoubiquitylated these substrates suggests that the mono-events
observed here have biological relevance. We demonstrated that E3s
appear hyperactivated for autoubiquitylation in the presence of
most DUBs (Fig. 5). This effect could be mediated by conformational
change occurring after deposition of ubiquitin to substrate, or
through simple interaction with the DUB. Because USP33c and
DEN1 were not ubiquitylated in vitro by Murf1 (Fig. 1C column 3,
rows 17 and 22, respectively) but mediated this E3-hyperactivation
under similar conditions (Fig. 5A), we have limited evidence to sup-
port the latter model. Because ubiquitin itself was present as a sub-
strate on the array, we learned that most E3s here tested do not
generate free chains in vitro, but Praja1 does (Fig. 1A compare
TUBEs to FK2 detection). We demonstrated that most DUBs do not
auto-deubiquitylate; nor, in fact, do most act to completely deu-
biquitylate any other DUBs. By visualizing both poly- and mono-
ubiquitin on substrates we were able to observe several characteristic
activity behaviors from among the DUBs; behaviors not apparent in
studies with free chains considering that all DUBs tested cleaved
free chains (loss of signal in Fig. 4 rows 1, TUBEs detection, or Figs.
S1–S5 rows 30 TUBEs detection). Namely, we have demonstrated
that some DUBs cleave chains promiscuously (USP28); some cleave
chains with substrate speciﬁcity (USP15); some are selective by sub-
strate and cleave “all or nothing” (USP21c) consistent with a model in
which the DUB removes chains in toto but only from certain sub-
strates; and ﬁnally, some DUBs promiscuously cleave chains, butshow selectivity in the removal of the ﬁnal mono-UB (PLPro and
PLP2). Interestingly, some of these proﬁles have been proposed
based on structural prediction of differential interaction among
DUB, substrate, and ubiquitin [31].
Two obvious and unexplored questions arising from the current
study are 1) what is the biological signiﬁcance of DUB mono-
ubiquitylation, and 2) is there physiological signiﬁcance to the sub-
strates identiﬁed in vitro for the Coronaviral DUBs (e.g. promoting
infection of host)? The most well-studied consequence to DUB
ubiquitylation is the hyperactivation of Ataxin3 activity [19]. Prelimi-
nary experiments aimed at exploring this possibility for other select-
ed enzymes suggested that this was not, in fact, a functional
consequence shared by other DUBs (data not shown). Nothing has
yet been attempted to address the second question, but it is worth
noting that a ubiquitylated membrane receptor has been reported
to be substrate of USP4 (itself the putative substrate of PLPro) [32];
and manipulation of host receptors seems a likely target for invading
microorganisms that require endocytosis (and lysosomal avoidance)
for infection.
The ability of substrates to dictate the extent of their own
ubiquitylation and selectively interact with DUBs points to a model
of simple structural recognition, in agreement with recent discoveries
[33,34]. While regulatory cofactors, non-functional inhibitory interac-
tions, spatio-temporal regulation, carefully balanced opposing enzy-
matic activities, and all other manners of cellular complexity will
undoubtedly impact physiology, this system nonetheless appears
particularly amenable to reductionist study. Regardless of which sub-
strates or ligases are used, the current work shows both technical fea-
sibility and biological advantage of examining chains and substrates
together when characterizing DUB activity.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2012.05.006.
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